Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14464259 | 0.89 | MEN1 (0.50) | MEN1KMT2ATSHRRECQLCNR1 | |
| SCHEMBL15259129 | 0.89 | MEN1 (0.50) | MEN1KMT2ATSHRRECQLCNR1 | |
| SCHEMBL15444479 | 0.89 | MEN1 (0.50) | MEN1KMT2ATSHRRECQLCNR1 | |
| SCHEMBL19871303 | 0.89 | MEN1 (0.50) | MEN1KMT2ATSHRRECQLCNR1 | |
| SCHEMBL17145177 | 0.86 | MEN1 (0.61) | MEN1KMT2ATSHRRECQL | |
| SCHEMBL16203711 | 0.86 | TSHR (0.58) | MEN1KMT2ATSHRCNR1KDM4E | |
| SCHEMBL13172394 | 0.85 | MEN1 (0.56) | MEN1KMT2ATSHRRECQLALDH1A1 | |
| SCHEMBL280281 | 0.84 | TSHR (0.61) | MEN1KMT2ATSHRCNR1KDM4E | |
| SCHEMBL3821431 | 0.84 | TSHR (0.70) | MEN1KMT2ATSHRRECQLALDH1A1 | |
| SCHEMBL23190300 | 0.84 | MEN1 (0.58) | MEN1KMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8911718-B2 | Methods for preparing polymeric reagents | NEKTAR THERAPEUTICS (US) | 2014-12-16 | — | — | US | disclosed |
| US-8722732-B2 | Oligomer-calcimimetic conjugates and related compounds | NEKTAR THERAPEUTICS (US) | 2014-05-13 | — | — | US | disclosed |
| US-8703115-B2 | Methods for preparing conjugates | NEKTAR THERAPEUTICS (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140107349-A1 | Methods for Preparing Polymeric Reagents | NEKTAR THERAPEUTICS (US) | 2014-04-17 | — | — | US | disclosed |
| US-8507653-B2 | Factor IX moiety-polymer conjugates having a releasable linkage | NEKTAR THERAPEUTICS (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130184443-A1 | Methods for Preparing Conjugates | NEKTAR THERAPEUTICS (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120238621-A1 | Oligomer-Calcimimetic Conjugates and Related Compounds | NEKTAR THERAPEUTICS (US) | 2012-09-20 | — | — | US | disclosed |
| US-8173597-B2 | Modified recombinant factor VIII and von Willebrand factor and methods of use | BAXTER INTERNATIONAL INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8133865-B2 | Two polymer chains (especially polyethylene oxide) connected to each other through a fluorenedicarbamoylmethyl group, which in turn is connected to an amine active agent by a releasable carbamate linkage; increased in vivo half-life | NEKTAR THERAPEUTICS (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090247459-A1 | MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE | BAXTER INTERNATIONAL INC. | 2009-10-01 | — | — | US | disclosed |
| US-20080234193-A1 | Von Willebrand factor-and factor VIII-polymer conjugates having a releasable linkage | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080188414-A1 | In vivo half life; reversible pegylation using such as carbamate connector; synthesis | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247459-A1 | MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE | F8, F5, F13B | MEN1 3264/4885KMT2A 2976/4885TSHR 1108/4885 |
| US-20120238621-A1 | Oligomer-Calcimimetic Conjugates and Related Compounds | CALCR, CALCB, CALCA | MEN1 86/4885KMT2A 4536/4885TSHR 1894/4885 |
| US-20130184443-A1 | Methods for Preparing Conjugates | SI, CD44, ABCG2 | MEN1 1376/4885KMT2A 3087/4885TSHR 2617/4885 |
| US-20080188414-A1 | In vivo half life; reversible pegylation using such as carbamate connector; synthesis | F9, F13A1, F13B | MEN1 1242/4885KMT2A 1790/4885TSHR 921/4885 |
| US-20080234193-A1 | Von Willebrand factor-and factor VIII-polymer conjugates having a releasable linkage | F8, F13A1, F13B | MEN1 1749/4885KMT2A 656/4885TSHR 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.